At the 67th World Health Assembly in Geneva in May 2014, a resolution was adopted on Health intervention and technology assessment in support of universal health coverage. Prof David Haslam, Chair of NICE, representing the UK Mission Geneva, addressed the Assembly during a panel session on the role

Pritaporn Kingkaew has been a researcher at HITAP since 2007. She graduated from a joint programme between Srinakharinwirot University, Thailand and the University of Nottingham, UK in 2007 with a Bachelor’s degree in Pharmacy. In 2009, she was awarded the HITAP scholarship to pursue a Master’s degree in Health Economics from the University of York

Welcome to iDSI, the international Decision Support Initiative. We provide a platform for supporting low and middle income country (LMIC) policymakers in making better use of healthcare resources to generate maximum health, in their journeys towards universal health coverage (UHC).

Kalipso Chalkidou , Amanda Glassman , Robert Marten , Jeanette Vega , Yot Teerawattananon , Nattha Tritasavit , Martha Gyansa-Lutterodt , Andreas Seiter Marie Paule Kieny , Karen Hofmani , Anthony J Culyerj Abstract Governments in low- and middle-income countries are legitimizing the imp

    202-206-2555health research topics,healthy research for healthy nation,Priority setting,ประเทศไทย

Abstract As COVID-19 ravages the world, many countries are faced with the grim reality of not having enough critical-care resources to go around. Knowing what could be in store, the Thai Ministry of Public Health called for the creation of an explicit protocol to determine how these resources are

The Health Intervention and Technology Assessment Program (HITAP), a member of the International Decision Support Initiative (iDSI) organised a side meeting titled “Attain & Sustain Health Gains: Incorporating Value-For-Money in the Universal Health Coverage Dialogue” at the Prince Mahidol Award

Increasing incidence of non-communicable diseases (NCDs) creates epidemiological and economic burdens everywhere and influences everyone regardless of sex and age.12 Four main NCDs (cardiovascular diseases, diabetes, cancer, and chronic respiratory disease) account for over 12 million premature deat

The purpose of this study is to compare the cost-utility of each treatment option available today in order to determine the most cost-effective treatment compared with standard treatment in the social perspective. Research methodology is an economic evaluation by using the markov model to compare the cost and utility of treatment options of new pat

Usa Chaikledkaew BSc(Pharm), MA, PhD*,** * Social and Administrative Pharmacy Excellence Research (SAPER) Unit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand ** Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thail